TerminatedPhase 2NCT02240706

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Boehringer Ingelheim
Principal Investigator
Boehringer Ingelheim
Boehringer Ingelheim
Intervention
Best Supportive Care(procedure)
Enrollment
27 enrolled
Eligibility
18 years · All sexes
Timeline
20152019

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02240706 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials